Celgene Announces Phase I/II Data Evaluating Clinical Benefit of REVLIMID in Combination with Standard R-CHOP Chemotherapy for Patients with Untreated Diffuse Large B-Cell Lymphoma

Celgene International Sàrl CELG announced that clinical data from two studies evaluating the use of REVLIMID with standard R-CHOP* chemotherapy in patients with untreated diffuse large B cell or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland. In a phase I/II study conducted by investigators at the Mayo Clinic, 12 patients received REVLIMID at doses of 15 mg, 20 mg or 25 mg on days 1-10 of each 21-day cycle with standard R-CHOP chemotherapy to determine the maximum tolerated dose of REVLIMID. There were no dose-limiting toxicities observed.